Kringle Pharma,Inc. (4884) Other
Market cap
¥2.7B
P/E ratio
-2.3x
Kringel Pharma develops treatments for rare diseases like spinal cord injury and ALS using recombinant human HGF protein technology for medical institutions and pharma partners.
| 2015/09 | 2016/09 | 2017/09 | 2018/09 | 2019/09 | 2020/09 | 2021/09 | 2022/09 | 2023/09 | 2024/09 | 2025/09 | |
| Return on Assets | - | - | - | - | -73.8 | 3.8 | -2.2 | -0.9 | -9.5 | -8.8 | -7.3 |
| Return on equity (%) | - | - | - | ||||||||
| Employees | 2 | 2 | 5 | 5 | 6 | 9 | 11 | 12 | 13 | 15 | 17 |